Natixis Advisors LLC Acquires 7,705 Shares of AbbVie Inc. $ABBV

Natixis Advisors LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 0.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,304,890 shares of the company’s stock after buying an additional 7,705 shares during the period. Natixis Advisors LLC’s holdings in AbbVie were worth $298,154,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Eclectic Associates Inc. ADV raised its stake in AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after buying an additional 45 shares during the period. Weil Company Inc. lifted its stake in shares of AbbVie by 2.3% during the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after buying an additional 46 shares during the last quarter. Hardin Capital Partners LLC lifted its stake in shares of AbbVie by 1.4% during the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after buying an additional 46 shares during the last quarter. Dogwood Wealth Management LLC lifted its stake in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after buying an additional 46 shares during the last quarter. Finally, Quantum Private Wealth LLC lifted its stake in shares of AbbVie by 2.0% during the 4th quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock worth $543,000 after buying an additional 46 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

AbbVie Trading Down 2.3%

Shares of NYSE ABBV opened at $212.63 on Tuesday. The business’s 50 day moving average is $208.56 and its 200-day moving average is $219.58. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The firm has a market cap of $375.67 billion, a P/E ratio of 104.74, a price-to-earnings-growth ratio of 0.75 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the company earned $2.46 EPS. The company’s revenue was up 12.4% on a year-over-year basis. Analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ABBV shares. Morgan Stanley raised their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Canaccord Genuity Group raised their target price on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Guggenheim reiterated a “buy” rating and set a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 target price on shares of AbbVie in a research note on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.